

# SAFETY DATA SHEET



## Furosemide Injection Formulation

Version  
2.13

Revision Date:  
06.04.2024

SDS Number:  
632213-00016

Date of last issue: 30.09.2023  
Date of first issue: 03.05.2016

---

### Section 1: Identification

**Product identifier** : Furosemide Injection Formulation

**Recommended use of the chemical and restrictions on use**

Recommended use : Veterinary product  
Restrictions on use : Not applicable

**Manufacturer or supplier's details**

Company : MSD

Address : 50 Tuas West Drive  
Singapore - Singapore 638408

Telephone : +1-908-740-4000

Emergency telephone number : 65 6697 2111 (24/7/365)

E-mail address : EHSDATASTEWARD@msd.com

---

### Section 2: Hazard identification

**Classification of the substance or mixture**

Specific target organ toxicity - : Category 2 (Kidney, Liver)  
repeated exposure

**GHS Label elements, including precautionary statements**

Hazard pictograms :



Signal word : Warning

Hazard statements : H373 May cause damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Precautionary statements :

**Prevention:**

P260 Do not breathe mist or vapours.

**Response:**

P314 Get medical advice/ attention if you feel unwell.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

# SAFETY DATA SHEET



## Furosemide Injection Formulation

Version 2.13 Revision Date: 06.04.2024 SDS Number: 632213-00016 Date of last issue: 30.09.2023 Date of first issue: 03.05.2016

---

### Other hazards which do not result in classification

None known.

---

## Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Concentration (% w/w)
Furosemide	54-31-9	>= 1 -< 10

---

## Section 4: First-aid measures

### Description of necessary first-aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.

### Most important symptoms and effects, both acute and delayed

Risks : May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

### Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

---

## Section 5: Fire-fighting measures

### Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

# SAFETY DATA SHEET



## Furosemide Injection Formulation

Version  
2.13

Revision Date:  
06.04.2024

SDS Number:  
632213-00016

Date of last issue: 30.09.2023  
Date of first issue: 03.05.2016

---

### Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Nitrogen oxides (NOx)  
Carbon oxides  
Sulphur oxides  
Chlorine compounds

### Special protective actions for fire-fighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

## Section 6: Accidental release measures

### Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

### Methods and materials for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**Furosemide Injection Formulation**

---

Version 2.13	Revision Date: 06.04.2024	SDS Number: 632213-00016	Date of last issue: 30.09.2023 Date of first issue: 03.05.2016
-----------------	------------------------------	-----------------------------	---

---

**Section 7: Handling and storage****Precautions for safe handling**

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe mist or vapours.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**Conditions for safe storage, including any incompatibilities**

Conditions for safe storage : Keep in properly labelled containers.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

---

**Section 8: Exposure controls/personal protection****Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Furosemide	54-31-9	TWA	200 µg/m <sup>3</sup>	Internal
		TWA	OEB 2 (>=100 - 1000 µg/m <sup>3</sup> )	Internal

**Appropriate engineering control measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-

# SAFETY DATA SHEET



## Furosemide Injection Formulation

Version  
2.13

Revision Date:  
06.04.2024

SDS Number:  
632213-00016

Date of last issue: 30.09.2023  
Date of first issue: 03.05.2016

---

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Laboratory operations do not require special containment.

### Individual protection measures, such as personal protective equipment (PPE)

Eye/face protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin protection	: Work uniform or laboratory coat.
Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	: Particulates type
Hand protection	
Material	: Chemical-resistant gloves

---

### Section 9: Physical and chemical properties

Appearance	: Aqueous solution
Colour	: yellow
Odour	: No data available
Odour Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available

# SAFETY DATA SHEET



## Furosemide Injection Formulation

Version 2.13      Revision Date: 06.04.2024      SDS Number: 632213-00016      Date of last issue: 30.09.2023  
Date of first issue: 03.05.2016

---

Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Particle characteristics		
Particle size	:	Not applicable

---

### Section 10: Stability and reactivity

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

### Section 11: Toxicological information

Information on likely routes of exposure	:	Inhalation
		Skin contact
		Ingestion
		Eye contact

#### Acute toxicity

Not classified based on available information.

# SAFETY DATA SHEET



## Furosemide Injection Formulation

Version 2.13      Revision Date: 06.04.2024      SDS Number: 632213-00016      Date of last issue: 30.09.2023  
Date of first issue: 03.05.2016

---

### Components:

#### **Furosemide:**

Acute oral toxicity : LD50 (Rat): 2,600 mg/kg  
LD50 (Dog): 2,000 mg/kg  
LD50 (Rabbit): 800 mg/kg

Acute toxicity (other routes of administration) : LD0 (Humans): 6 - 29 mg/kg  
Application Route: Intravenous  
LD50 (Rat): 800 mg/kg  
Application Route: Intravenous

#### **Skin corrosion/irritation**

Not classified based on available information.

#### **Serious eye damage/eye irritation**

Not classified based on available information.

#### **Respiratory or skin sensitisation**

#### **Skin sensitisation**

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

#### **Germ cell mutagenicity**

Not classified based on available information.

### Components:

#### **Furosemide:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Test system: mouse lymphoma cells  
Result: positive

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Test system: mammalian liver cells  
Result: negative

Test Type: Chromosome aberration test in vitro  
Test system: Chinese hamster ovary cells  
Result: positive

Test Type: In vitro sister chromatid exchange assay in mammalian cells

**Furosemide Injection Formulation**

Version 2.13	Revision Date: 06.04.2024	SDS Number: 632213-00016	Date of last issue: 30.09.2023 Date of first issue: 03.05.2016
-----------------	------------------------------	-----------------------------	---

Test system: Chinese hamster cells  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Chinese hamster  
Application Route: Ingestion  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****Furosemide:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 104 weeks  
LOAEL : 16 mg/kg body weight  
Result : equivocal

Species : Mouse  
Application Route : Ingestion  
Exposure time : 2 Years  
LOAEL : 91 mg/kg body weight  
Result : positive

**Reproductive toxicity**

Not classified based on available information.

**Components:****Furosemide:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
General Toxicity - Parent: NOAEL: 90 mg/kg body weight  
Result: No effects on reproduction parameters

Test Type: One-generation reproduction toxicity study  
Species: Mouse  
Application Route: Ingestion  
General Toxicity - Parent: NOAEL: 200 mg/kg body weight  
Result: No effects on reproduction parameters

Effects on foetal development : Test Type: Fertility/early embryonic development

**Furosemide Injection Formulation**

Version 2.13	Revision Date: 06.04.2024	SDS Number: 632213-00016	Date of last issue: 30.09.2023 Date of first issue: 03.05.2016
-----------------	------------------------------	-----------------------------	---

ment	Species: Rat Application Route: Ingestion General Toxicity Maternal: LOAEL: 50 mg/kg body weight Developmental Toxicity: NOAEL: 300 mg/kg body weight Result: No embryotoxic effects, No teratogenic effects
	Test Type: Fertility/early embryonic development Species: Mouse Application Route: Ingestion General Toxicity Maternal: LOAEL: 25 mg/kg body weight Result: Maternal toxicity observed., Fetal effects
	Test Type: Fertility/early embryonic development Species: Rabbit Application Route: Ingestion General Toxicity Maternal: LOAEL: <= 12 mg/kg body weight Developmental Toxicity: LOAEL: 12.5 mg/kg body weight Result: Maternal toxicity observed., Reduced number of viable fetuses
	Test Type: Fertility/early embryonic development Species: Rabbit Application Route: Ingestion General Toxicity Maternal: LOAEL: 15 mg/kg body weight Result: Maternal toxicity observed., No effects on foetal development

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

May cause damage to organs (Kidney, Liver) through prolonged or repeated exposure.

**Components:****Furosemide:**

Exposure routes	:	Ingestion
Target Organs	:	Kidney
Assessment	:	Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

**Repeated dose toxicity****Components:****Furosemide:**

Species	:	Dog
NOAEL	:	4 mg/kg
LOAEL	:	8 mg/kg
Application Route	:	Ingestion
Exposure time	:	12 Months
Target Organs	:	Kidney

# SAFETY DATA SHEET



## Furosemide Injection Formulation

Version 2.13 Revision Date: 06.04.2024 SDS Number: 632213-00016 Date of last issue: 30.09.2023 Date of first issue: 03.05.2016

---

Symptoms : Blood disorders  
Remarks : Significant toxicity observed in testing

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

#### **Furosemide:**

Inhalation : Remarks: May be harmful if inhaled.  
Skin contact : Remarks: May irritate skin.  
Eye contact : Remarks: May cause eye irritation.  
Ingestion : Symptoms: Kidney disorders, Headache, electrolyte imbalance, dry mouth, hearing loss, Irregular cardiac activity, Gastrointestinal disturbance, hypotension

---

## Section 12: Ecological information

### Toxicity

#### Components:

#### **Furosemide:**

Toxicity to fish : LC50 : 500 mg/l  
Exposure time: 96 h

### Persistence and degradability

No data available

### Bioaccumulative potential

#### Components:

#### **Furosemide:**

Partition coefficient: n-octanol/water : log Pow: 2.03

### Mobility in soil

No data available

### Other adverse effects

No data available

---

## Section 13: Disposal considerations

### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.

---

# SAFETY DATA SHEET



## Furosemide Injection Formulation

Version 2.13      Revision Date: 06.04.2024      SDS Number: 632213-00016      Date of last issue: 30.09.2023  
Date of first issue: 03.05.2016

---

If not otherwise specified: Dispose of as unused product.

### Section 14: Transport information

#### International Regulations

##### UNRTDG

UN number	:	Not applicable
UN proper shipping name	:	Not applicable
Transport hazard class(es)	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Environmentally hazardous	:	no

##### IATA-DGR

UN/ID No.	:	Not applicable
UN proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Packing instruction (cargo aircraft)	:	Not applicable
Packing instruction (passenger aircraft)	:	Not applicable

##### IMDG-Code

UN number	:	Not applicable
UN proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
EmS Code	:	Not applicable
Marine pollutant	:	Not applicable

#### Transport in bulk according to IMO instruments

Not applicable for product as supplied.

#### Special precautions for user

Not applicable

---

### Section 15: Regulatory information

#### Safety, health and environmental regulations specific for the product in question

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and Environmental Protection and Management (Hazardous Substances) Regulations : Not applicable

# SAFETY DATA SHEET



## Furosemide Injection Formulation

Version 2.13 Revision Date: 06.04.2024 SDS Number: 632213-00016 Date of last issue: 30.09.2023 Date of first issue: 03.05.2016

---

Fire Safety (Petroleum and Flammable Materials) Regulations : Not applicable

### The components of this product are reported in the following inventories:

AICS : not determined  
DSL : not determined  
IECSC : not determined

---

## Section 16: Other information

Revision Date : 06.04.2024

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECL - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Trans-

# SAFETY DATA SHEET



## Furosemide Injection Formulation

Version  
2.13

Revision Date:  
06.04.2024

SDS Number:  
632213-00016

Date of last issue: 30.09.2023  
Date of first issue: 03.05.2016

---

portation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN